Aims and objectives of this session
To discuss various predictive and prognostic factors in RCC.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

**Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study**

**Institutes:** Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Incheon, South Korea,  
St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea,  
Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Dept. of Urology, Bucheon, South Korea,  
Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea,  
Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea,  
Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea,  
Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea,  
College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

---

**Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis**

**By:** Larcher A., Muttin F., Nini A., Trevisani F., Ripa F., Cianflone F., Carenzi C., Dell’Oglio P., Rigatti P., Dehó F., Montorsi F., Capitanio U., Bertini R.  
**Institutes:** IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy,  
Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

---

**External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus**

**Institutes:** Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America,  
University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America,  
University Vita-Salute, Dept. of Urology, Milan, Italy,  
Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain,  
University of Miami, Dept. of Urology, Miami, United States of America,  
University of Southern California, Dept. of Urology, Los Angeles, United States of America,  
University of California-Davis, Dept. of Urology, Sacramento, United States of America,  
University of Turin, Dept. of Urology, Turin, Italy,  
University of Frankfurt, Dept. of Urology, Frankfurt, Germany,  
University of Heidelberg, Dept. of Urology, Heidelberg, Germany,  
New York University School of Medicine, Dept. of Urology, New York, United States of America.
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study
By: Rossi S.1, Hsu R.1, Blick C.2, Goh V.3, Hanbury D.4, Nathan P.5, Nicol D.6, Fleming S.7, Sweeting M.8, Watson C.9, Wilson E.10, Stewart G.1
Institutes: 1Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, 2Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 3Guy’s & St Thomas’ Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, 4Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 5Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, 6Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 7Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, 8University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, 9National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, 10University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma
By: Pecoraro A.1, Larcher A.1, Nini A.1, Muttin F.1, Stabile A.1, Di Trapani E.1, Carenzi C.1, Trevisani F.1, De Cobelli F.2, Gaboardi F.1, Guazzoni G.3, Briganti A.1, Montorsi F.1, Bertini R.1, Capitanio U.1
Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, 3Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients
Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, 3Medical University of Vienna, Dept. of Urology, Austria, 4Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, 5Carl–Thiem–Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, 6Vita–Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, 8Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, 9Julius–Maximilians–University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, 10University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 11University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 12University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 13Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, 14Charles University In Prague, Dept. of Urology, Pilsen, Czech Republic, 15Medical University Graz, Dept. of Urology, Graz, Austria, 16Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, 17Ludwig–Maximilians–University, Dept. of Urology, Munich, Germany

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S.1, Beisland C.2, Gudmundsson E.3, Stewart G.4, Lam T.5, Gietzmann W.6, Zakikhani P.6, MarconcI L.7, Williams S.13, Powles T.8, Van Werkhoven E.5, Meijer R.P.12, Ljungberg B.11, Bex A.10

Institutes: 1Lund University, Dept. of Clinical Sciences, Malmö, Sweden, 2Haukeland University Hospital, Dept. of Urology, Bergen, Norway, 3Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, 4University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 7Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 8Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 9The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, 10The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, 11Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 12University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, 13University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: Gild P.1, Von Landenberg N.1, Sun M.1, Develasco G.2, Brastianos P.3, Menon M.4, Fisch M.5, Chun F.6, Nguyen P.6, Trinh Q-D.6, Choueiri T.2

Institutes: 1Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, 2Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 3Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, 4Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 5University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 6Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell
carcinoma
By: Izumi K.¹, Saito K.¹, Nakayama T.¹, Fukuda S.², Fukushima H.³, Uehara S.⁴, Koga F.³, Yonese J.⁴, Kageyama Y.², Kihara K.⁵, Fujii Y.⁵
Institutes: ¹Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, ²Saitama Cancer Center, Dept. of Urology, Saitama, Japan, ³Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, ⁴Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ⁵Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Utility of chest x-ray in follow-up of pT1 renal cell carcinoma
By: Rizzo M.¹, Umari P.¹, Pavan N.¹, Liguori G.¹, Verzotti E.¹, Cancellieri L.¹, Mottrie A.², Minervini A.³, Trombetta C.³
Institutes: ¹Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, ²Onze-Lieve-Vrouwenziekenhuis, Dept. of Urology, Aalst, Belgium, ³University Hospital Careggi, Dept. of Urology, Florence, Italy

Organ confined renal cell carcinoma - are the current guidelines sufficient?
By: Frees S.¹, Kamal M.¹, Nestler S.², Bidnur S.³, Neisius A.¹, Jaeger W.¹, Thomas C.¹, Thüroff J.⁴, Roos F.¹
Institutes: ¹University Medical Center, Dept. of Urology, Mainz, Germany, ²Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, ³University Hospital Careggi, Dept. of Urology, Florence, Italy, ⁴Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, ⁵Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study
By: Tondut L.¹, Peyronnet B.¹, Bernhard J-C.², Vaessen C.², Doumerc N.⁴, Sebe P.⁵, Pradere B.⁶, Guillonneau B.⁷, Nouhaud F.X.⁷, Brichart N.⁸, Alimi Q.¹, Beauval J-B.³, Rammal A.³, De La Taille A.¹, Baumert H.¹, Droupy S.¹², Bruyere F.⁵, Roupret M.³, Mejean A.¹³, Bensalah K.¹

Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data
By: Camp C.¹, O’Hara J.¹, Hughes D.¹, Adshead J.²
Institutes: ¹Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, ²Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom